|
|
|
| Application of Different Doses of Tigrillo in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention with Reischemia |
| ZHANG Hui-qin, WANG Zhi-gang, WANG Xiao-ni |
| Department of Cardiovascular Medicine,Xianyang Hospital of Yan'an University,Xianyang Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of different doses of Tigrillo in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) for reperfusion.【Methods】A total of 64 AMI patients who underwent PCI surgery Xianyang Hospital of Yan'an University from April 2020 to November 2021 were selected and divided into an observation group and a control group based on different treatment methods,with 32 patients in each group. Comparison of the two groups before and after treatment was conducted including platelet function [Platelet aggregation rate,platelet count,enzyme membrane glycoprotein 63 (CD63) α Granular membrane glycoprotein 62p (CD62p)],coronary artery blood flow parameters [Peak systolic blood flow (SPV),peak diastolic blood flow (DPV),coronary flow reserve (CFVR)],myocardial injury indicators[Ischemic modified albumin (IMA),cardiac troponin I (cTnI),myoglobin (Mb),creatine kinase isoenzyme (CK-MB) ],inflammatory factors [Hypersensitivity C-reactive protein (hs-CRP),intercellular adhesion molecule-1 (ICAM-1),macrophage derived chemokine (MDC),interleukin-10 (IL-10)],and the incidence of adverse reactions after treatment.【Results】After treatment,the platelet aggregation rate,platelet count,CD63,and CD62p in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The DPV,SPV,and CFVR of both groups of patients were higher than before treatment,and the observation group was higher than the control group (P<0.05); The levels of IMA,cTnI,Mb,and CK-MB in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The levels of hs-CRP,ICAM-1,MDC,and IL-10 in both groups were lower than before treatment,and the observation group was lower than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).【Conclusion】The treatment of AMI patients with load dose Tigrillo can improve platelet function,coronary artery blood flow,alleviate myocardial injury,and reduce the expression level of inflammatory factors in patients with reperfusion after PCI,which is of great significance for improving patient prognosis.
|
|
Received: 28 July 2022
|
|
|
|
|
|
[1] BHATT D L,LOPES R D,HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes: A review[J].JAMA,2022,327(7):662-675.
[2] 董立丽.替格瑞洛在急性冠脉综合征中的临床应用进展[J].天津药学,2021,33(3):69-72.
[3] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
[4] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[5] 何奔,韩雅玲.中国ST段抬高型心肌梗死救治现状及应有对策[J].中华心血管病杂志,2019,47(2):82-84.
[6] 张承花,陈静波,李建文,等.替格瑞洛用于急性心肌梗死经皮冠状动脉介入围术期对冠状动脉血流和炎症反应及心肌酶谱的影响[J].中国医药,2021,16(5):661-665.
[7] 李阳,于海初.急性心肌梗死经皮冠状动脉介入治疗术后应用替格瑞洛联合阿司匹林治疗发生脑出血一例[J].中国循环杂志,2016,31(12):1164.
[8] 罗勇,陈青梅.不同剂量替格瑞洛对急性心肌梗死患者PCI后冠脉血流、炎症反应及心肌酶谱的影响[J].海南医学院学报,2018,24(2):161-164.
[9] 田峰,白晓梅,王桂东.替格瑞洛和氯吡格雷对老年急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术后并发症及预后的影响[J].河北医学,2021,27(2):313-317.
[10] 陈琦,林子舒,马天一,等.负荷量替格瑞洛联合丹红注射液防治急性前壁STEMI患者PCI后再灌注心律失常疗效及对心肌损伤指标的影响[J].现代中西医结合杂志,2021,30(23):2555-2560.
[11] 黎美兰,陈世雄,林慕如,等.急性心肌梗死患者PCI治疗前后血清Lp-PLA2、IMA变化[J].中国病案,2020,21(8):102-104.
[12] 付小娟,程璐,刘结清.cTnI、CK-MB联合Myo在急性心肌梗死诊断中的应用价值分析[J].现代诊断与治疗,2021,32(20):3267-3269.
[13] 张玥,谭晓.促红细胞生成素对ST段抬高型心肌梗死患者介入术后再灌注性心律失常的影响及可能机制[J].中国医药,2020,15(3):336-340. |
|
|
|
2023, Vol. 40 
